Technology & Software Global On demand · 24-48h

Global Exosome Isolation Service Market Strategic Research Report

Global Exosome Isolation Service Market Strategic Research R…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Exosome Isolation Service Market
$8672025
5.8%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Ultracentrifugation, Immunomagnetic Bead Method, Size Exclusion Chromatography

By Application: Early Cancer Screening, Neurological Disease Diagnosis, Drug Delivery System Development, Regenerative Medicine, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Codiak Biosciences, Aethlon Medical, NanoSomix, Aruna Bio, Creative Biostructure, AMSBIO, Everzom, System Biosciences, Creative Biolabs, Frontage Labs, Lonza, Capital Biosciences, Miltenyi Biotec, Novus Biologicals, Clara Biotech, Immunostep, ExosomeDx, Irvine Scientific, Beckman Coulter, Stratech, QIAGEN, Lifeasible

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 154 pages
Market size 2025
$867
Million USD
Forecast CAGR
5.8%
2025-2032
Forecast 2032
$1286.5
Projected
Области
5
Asia Pacific · Latin America · MEA · Europe · North America

Обзор

Scope of the Report

The global Exosome Isolation Service market size is predicted to grow from US$ 867 million in 2025 to US$ 1,286 million in 2032; it is expected to grow at a CAGR of 5.8% from 2026 to 2032.

To address the challenges in exosome research, such as the complexity of sample composition, minute size, diverse biomarkers, and the low throughput and lack of standardization of traditional analytical methods, specialized exosome analysis services have emerged. Since the widespread recognition of the biological value of exosomes and breakthroughs in separation and detection technologies in the early 21st century, this service has evolved from internal laboratory methods into a key supporting industry for translational medicine and precision medicine. Currently, exosome analysis services have developed into a high-throughput, multi-omics integrated analysis system encompassing exosome isolation and identification, nanoparticle tracking, proteomics, transcriptomics, metabolomics, and functional validation. Widely applied in areas such as early cancer screening, neurological disease diagnosis, drug delivery system development, regenerative medicine, and basic life science research, this professional research service system provides researchers and clinical developers with standardized, one-stop solutions from sample to data, significantly accelerating the process of biomarker discovery, mechanism research, and industrial application.

As an emerging force in the biotechnology field, exosome analysis services are undergoing a transformation from "technological exploration" to "clinical application." Driven by technological innovation, application expansion, and standardization efforts, the industry will break through traditional cyclical patterns and evolve towards high value-added and high reliability. Companies need to seize the dual opportunities of technological upgrading and demand upgrading, and through industrial chain collaboration and technological breakthroughs, occupy a strategic high ground in the global exosome landscape, providing innovative solutions for disease diagnosis and treatment, and health management, thus opening a new chapter in precision medicine and regenerative medicine.

This report presents a comprehensive overview of the global Exosome Isolation Service market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Ultracentrifugation
  • Immunomagnetic Bead Method
  • Size Exclusion Chromatography

Segment by Sample Source

  • Blood Samples
  • Urine Samples
  • Cell Culture Supernatant

Segment by Purity Standards

  • High Purity Separation
  • Medium Purity Separation

Segment by Application

  • Early Cancer Screening
  • Neurological Disease Diagnosis
  • Drug Delivery System Development
  • Regenerative Medicine
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Exosome Isolation Service market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Early Cancer Screening, Neurological Disease Diagnosis, Drug Delivery System Development evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Exosome Isolation Service Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 5.8%
Regional growth momentum
Market share by segment
Key metrics
Base value
$867
2025
Forecast
$1286.5
2032
CAGR
5.8%
2025–2032
Области
5
global
Key companies
Codiak BiosciencesAethlon MedicalNanoSomixAruna BioCreative BiostructureAMSBIOEverzomSystem Biosciences
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
UltracentrifugationImmunomagnetic Bead MethodSize Exclusion Chromatography
By Application
Early Cancer ScreeningNeurological Disease DiagnosisDrug Delivery System DevelopmentRegenerative MedicineOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Ultracentrifugation
  • 3.1.3 Immunomagnetic Bead Method
  • 3.1.4 Size Exclusion Chromatography
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Early Cancer Screening
  • 4.1.3 Neurological Disease Diagnosis
  • 4.1.4 Drug Delivery System Development
  • 4.1.5 Regenerative Medicine
  • 4.1.6 Other
  • 4.1.7 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Codiak Biosciences
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Aethlon Medical
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 NanoSomix
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Aruna Bio
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Creative Biostructure
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 AMSBIO
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Everzom
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 System Biosciences
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Creative Biolabs
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Frontage Labs
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Lonza
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Capital Biosciences
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Miltenyi Biotec
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Novus Biologicals
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Clara Biotech
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Immunostep
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 ExosomeDx
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Irvine Scientific
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Beckman Coulter
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Stratech
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 QIAGEN
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 Lifeasible
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Exosome Isolation Service market?
The global Exosome Isolation Service market is estimated at US$ 867 million in 2025 (base year) and is projected to reach US$ 1.29 billion by 2032.
What is the forecast CAGR for the Exosome Isolation Service market?
The market is expected to grow at a CAGR of 5.8% from 2026 to 2032, expanding from US$ 867 million in 2025 to US$ 1.29 billion in 2032, roughly 1.5 times its base-year value.
What is Exosome Isolation Service?
To address the challenges in exosome research, such as the complexity of sample composition, minute size, diverse biomarkers, and the low throughput and lack of standardization of traditional analytical methods, specialized exosome analysis services have emerged. Since the widespread recognition of the biological value of exosomes and breakthroughs in separation and detection technologies in the early 21st century, this service has evolved from internal laboratory methods into a key supporting industry for translational medicine and precision medicine.
What are the main segments of the Exosome Isolation Service market by type?
By type, the market is segmented into Ultracentrifugation, Immunomagnetic Bead Method and Size Exclusion Chromatography.
Which applications drive demand in the Exosome Isolation Service market?
Key applications covered include Early Cancer Screening, Neurological Disease Diagnosis, Drug Delivery System Development, Regenerative Medicine and Other.
Who are the key players in the Exosome Isolation Service market?
Key players profiled include Codiak Biosciences, Aethlon Medical, NanoSomix, Aruna Bio, Creative Biostructure, AMSBIO, Everzom and System Biosciences, among 22 companies covered in total.
Which regions and countries are covered for Exosome Isolation Service?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Exosome Isolation Service market?
As an emerging force in the biotechnology field, exosome analysis services are undergoing a transformation from "technological exploration" to "clinical application." Driven by technological innovation, application expansion, and standardization efforts, the industry will break through traditional cyclical patterns and evolve towards high value-added and high reliability.
What challenges does the Exosome Isolation Service market face?
To address the challenges in exosome research, such as the complexity of sample composition, minute size, diverse biomarkers, and the low throughput and lack of standardization of traditional analytical methods, specialized exosome analysis services have emerged.
Who should buy the Exosome Isolation Service market report?
The report is intended for manufacturers and solution providers, distributors and end users in Early Cancer Screening, Neurological Disease Diagnosis and Drug Delivery System Development, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Exosome Isolation Service market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3 500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.